#None #MiniMed 780G #Diabetes Technology #Instinct Sensor

MiniMed 780G System: A New Era in Diabetes Management

MiniMed Group, Inc., a renowned leader in insulin delivery systems, has recently achieved a significant milestone by securing the CE Mark for its MiniMed™ 780G system compatible with the Instinct sensor, developed by Abbott. This new addition expands the array of sensor choices available to users of its advanced automated insulin delivery (AID) system.

In an announcement made on March 10, 2026, que Dallara, CEO of MiniMed, emphasized that the company is committed to addressing the needs of those living with diabetes. With this latest update, MiniMed aims to reduce the daily management burden by providing more flexibility within an integrated system, backed by proven clinical outcomes.

Features of the MiniMed™ 780G System

The MiniMed™ 780G system stands out for its ability to automate insulin delivery and adjust doses every five minutes based on real-time glucose measurements. It's designed to help users manage their diabetes more effectively and with less hassle.

The system is now compatible with three sensors: the Guardian™ 4, Simplera Sync™, and the new Instinct sensor. Both Guardian™ 4 and Simplera Sync™ provide up to seven days of wear, whereas the Instinct sensor pushes the boundaries by offering a remarkable wear time of up to 15 days. Its compact design makes it the smallest and thinnest continuous glucose monitor (CGM) in the world, promoting discretion for users.

Anticipated Launch and User-Centric Approach

MiniMed plans to launch the MiniMed™ 780G system with the Instinct sensor across selected European countries this summer. This announcement will coincide with a presentation at the 19th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2026) scheduled for March 11-14, 2026, in Barcelona.

In the European market, the MiniMed™ 780G system caters to individuals aged two years and older who require insulin, whether they have type 1 or type 2 diabetes and administer a minimum of six units of insulin daily. Additionally, this system has also received CE Mark approval for use during pregnancy, enhancing its accessibility to pregnant women managing diabetes.

In contrast, the U.S. indication for the MiniMed™ 780G system is for individuals with type 1 diabetes aged seven years and older, along with adults with insulin-requiring type 2 diabetes. Clinical trials are currently evaluating its suitability for younger patients aged 2–6 years, although the FDA has not yet approved its use during pregnancy.

Expanding Options for Diabetes Management

Alongside the MiniMed™ 780G system, the CE Mark approval for the MiniMed Go™ Smart MDI system with the Instinct Go sensor is confirmed, with its rollout expected in select European countries also during the summer season. This extension showcases MiniMed's commitment to offering extensive choices for individuals managing diabetes through multiple daily injections.

Frequently Asked Questions

Q: What is the MiniMed™ 780G system?
A: It is MiniMed's most sophisticated automated insulin delivery system, designed to optimize insulin adjustments based on continuous glucose data.

Q: What makes the Instinct sensor stand out?
A: The Instinct sensor is notable for its up to 15 days of wearability, being discreet while providing crucial glucose monitoring support.

Conclusion

MiniMed is on a mission to enhance the lives of those living with diabetes globally. With the MiniMed™ 780G system, including the newly integrated Instinct sensor, the company continues to lead innovations in diabetes care. Their commitment to listening to patients and refining technology ensures that managing diabetes becomes less of a burden, allowing individuals to focus on living their lives fully and freely.

For more than 40 years, MiniMed has been at the forefront of insulin delivery solutions. The advances promised with the MiniMed™ 780G system signify not just technological improvement, but also a meaningful impact on the day-to-day management of diabetes for many individuals across Europe.